Research Spotlight: The efficacy and safety of β‑nicotinamide mononucleotide(NMN) supplementation in healthy middle‑aged adults…

The following is an overview of the research paper:

"The efficacy and safety of β‑nicotinamide mononucleotide(NMN) supplementation in healthy middle‑agedadults: a randomized, multicenter, double‑blind, placebo‑controlled, parallel‑group, dose‑dependent clinical trial" 

Aim

“…to test the effect of NMN supplementation on blood NAD concentration (primary outcome), safety, tolerability, and clinical efficacy (secondary outcomes) of NMN supplementation.”

Study protocol and method

• NMN 300mg, 600mg, 900mg OR placebo;

• 80 Indian ethnicity participants, 20 per group;

• Period of 60 days with check in at day 0, day 30, and day 60;

• 40-65 years healthy volunteers of both males and females;

• body mass index (BMI) between 18.5 and 35 kg/m2;

• not taking any supplements containing any form of niacin for 7 days prior to baseline and for the duration of the trial;

• multicenter, randomized, parallel, double- blinded, placebo-controlled;

• Location: Pune, India.

Measures

1. Blood for total NAD (non-specificity of NAD+ & NADH) [d0, d30, d60]

2. Blood & urinary measurement for general health markers [d0, d60]

3. 6 minute walking test (American Thoracic Society protocol for measuring endurance and energy)

4. Blood biological age algorithm (Aging.ai 3.0) [d0, d60]

5. Homeostasis Model Assessment ‐ Insulin Resistance [d0, d60]

6. 36‐Item Short Form Survey (SF‐36 Questionnaire)

Results

1. Blood NAD increased in NMN groups:

   1. 300mg group ~3x @d30&60;

   2. 600mg & 900mg groups ~4x @d30&60.

2. No significant improvement in blood or urinary health markers

3. Improvements in distance on 6 minute walking test

   1. 300mg group up 14%@d30 & 23%@d60

   2. 600mg & 900mg groups up ~30%@d30 & ~50%@d60

4. Blood age NMN groups did not age by a statistically significant outcome compared to placebo, no trend.

5. No significant improvement in insulin resistance in NMN groups.

6. Significant improvements in SF36 scores

   1. placebo group up 4%@d30 & 5%@d60 (for context)

   2. 300mg group up 6%@d30 & 10%@d60

   3. 600mg & 900mg groups up ~10%@d30 & ~15%@d60

Discussion

As supported by previous NMN clinical research, this study showed that NMN supplementation does significantly raise total circulating NAD significantly in middle aged and older individuals.The 600mg & 900mg groups had very similar outcomes, showing a clear tapering of the dose response curve. Overall perceived energy and wellbeing improved based on the survey scores, and was supported by improvements in 6 minute walking distances. As expected according to the potential mechanisms for NMN improving insulin sensitivity in diabetic groups, NMN did not increase sensitivity in healthy normal populations, supportive of a “recovering cellular health” hypothesis which is only relevant in cases of damage.

Of mention, only total NAD non-specific to NAD+ or NADH was measured. As the potential health implications of each does differ and a lower NAD+ to NADH ratio is non-ideal.

— — —

First published for nicesupplementco.com on 28th December 2023